Pubblicazioni

B- and T-cell responses after SARS-CoV-2 vaccination in patients with multiple sclerosis receiving disease modifying therapies. Immunological patterns and clinical implications

2022 - FRONTIERS IN IMMUNOLOGY

Iannetta, M.; Landi, D.; Cola, G.; Campogiani, L.; Malagnino, V.; Teti, E.; Coppola, L.; Di Lorenzo, A.; Fraboni, D.; Buccisano, F.; Grelli, S.; Mozzani, M.; Zingaropoli, M. A.; Ciardi, M. R.; Nisini, R.; Bernardini, S.; Andreoni, M.; Marfia, G. A.; Sarmati, L.

Rituximab plus chemotherapy provides no clinical benefit in a peripheral T-cell lymphoma not otherwise specified with aberrant expression of CD20 and CD79a. A case report and review of the literature

2020 - DIAGNOSTICS

Mangogna, A.; Cox, M. C.; Ruco, L.; Lopez, G.; Belmonte, B.; Di Napoli, A.

Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis

2019 - OPEN FORUM INFECTIOUS DISEASES

Ciardi, Maria R; Iannetta, Marco; Zingaropoli, Maria A; Salpini, Romina; Aragri, Marianna; Annecca, Rosanna; Pontecorvo, Simona; Altieri, Marta; Russo, Gianluca; Svicher, Valentina; Mastroianni, Claudio M; Vullo, Vincenzo

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

2017 - ADVANCES IN THERAPY

Salles, Gilles; Barrett, Martin; FoÃ , Robin; Maurer, Joerg; OâBrien, Susan; Valente, Nancy; Wenger, Michael; Maloney, David G.